Immunovant, Inc.

Equities

IMVT

US45258J1025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
28.95 ^USD	+1.97%		-5.70%	-31.28%

May. 24	Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	MT
Apr. 20	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT

Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023

February 12, 2024 at 07:06 am EST

Immunovant, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported net loss was USD 51.42 million compared to USD 63.23 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.49 a year ago.
For the nine months, net loss was USD 184.02 million compared to USD 151.53 million a year ago. Basic loss per share from continuing operations was USD 1.36 compared to USD 1.26 a year ago.

Latest news about Immunovant, Inc.

Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	May. 24	MT
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	Apr. 19	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	Apr. 19	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	Mar. 28	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	Mar. 13	MT
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	Feb. 23	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	Feb. 20	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	Feb. 15	MT
Immunovant Posts Narrower Fiscal Q3 Loss	Feb. 12	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
North American Morning Briefing : Jobs Report Tops -2-	Feb. 02	DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	Jan. 29	MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	Jan. 09
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Dec. 21	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	Dec. 21	MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	Dec. 20	DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	Dec. 20	MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	Dec. 20	CI
Top Premarket Decliners	Dec. 20	MT
Deutsche Bank Initiates Coverage on Immunovant With Buy Rating, $50 Price Target	Dec. 12	MT
Immunovant Insider Sold Shares Worth $490,697, According to a Recent SEC Filing	Dec. 05	MT
Immunovant Insider Sold Shares Worth $504,567, According to a Recent SEC Filing	Dec. 05	MT
Immunovant Insider Sold Shares Worth $490,668, According to a Recent SEC Filing	Dec. 05	MT
UBS Raises Immunovant Price Target to $56 From $55, Maintains Buy Rating	Dec. 01	MT

Chart Immunovant, Inc.

Duration

Period

More charts

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.

Sector

Biotechnology & Medical Research

Calendar

2024-06-30 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.95 USD

Average target price

50.43 USD

Spread / Average Target

+74.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUNOVANT, INC.	-31.28%	4.21B
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research